1. In Vivo
  2. >>Business Strategy

Therapeutic Area Partnerships: Faster, Earlier and Make Mine Cash

The rising dealmaking value of proof of concept (POC) was the key theme at Windhover's Therapeutic Area Partnerships meeting, (Oct. 24-26, 2007). In 2002 and 2003 companies paid roughly three times the value for Phase III products that they paid for Phase II. Now, candidates at Phase II (a proxy for POC) go for about the same price as Phase III drugs. What’s going on here and what role will Big Pharma and mid-size companies find themselves playing if the trend continues?

The words on everyone’s lips at Windhover’s second annual Therapeutic Area Partnerships meeting, October 24-26, in Philadelphia, were like an incantation. Proof-of-concept. The meeting, focused on licensing in four therapeutic areas (oncology, neurology, cardiovascular and metabolic) and during which the top partnering opportunities in each category were chosen, was nonetheless as much about dealmaking trends—particularly proof-of-concept (POC) as a value-inflection point—as about the specific candidates its participants highlighted.

Not so long ago—when Big Pharma still had the luxury of believing its pipelines were adequate to support their growth—POC...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.